21-Gene recurrence score assay in pN2-3 Early-Stage breast cancer: a national cancer database study

Clicks: 8
ID: 331422
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #372 of 381 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 381 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: The clinical utility of the 21-gene recurrence score (RS) for guiding adjuvant chemotherapy in patients with pN2-3 early-stage breast cancer (eBC) has not been evaluated in prospective trials. This study aims to assess adjuvant chemotherapy benefit in patients with pN2-3 eBC who underwent RS testing and had a RS ≤ 25. METHODS: We conducted a retrospective cohort study from the National Cancer Database (NCDB) among patients with hormone receptor-positive/HER2-negative, pN2-3 eBC diagnosed from 2010-2020 who underwent 21-gene RS testing (OncotypeDX) and had RS ≤ 25. Overall survival (OS) was compared between patients who received or did not receive chemotherapy, using propensity score (PS)-weighted Cox regression. RESULTS: Among 50,229 eligible patients with pN2-3 eBC, 3,110 (6%) underwent RS testing. Patients who underwent testing had longer OS than those who did not (5-year OS: 86% vs. 79%). Among tested patients, 2,058 (66%) had RS ≤ 25 (median: 15), and 68% of them received chemotherapy. At a median follow-up of 5.3 years, the PS-weighted hazard ratio for OS comparing chemotherapy to no chemotherapy was 0.62 (95% CI: 0.48-0.81; P = 0.0002; E-value: 2.13, 95% CI lower bound: 1.58). CONCLUSION: In this cohort of highly selected patients with hormone receptor-positive/HER2-negative pN2-3 eBC who underwent 21-gene RS testing and had RS ≤ 25, patients who received chemotherapy had a longer OS compared to those who did not receive chemotherapy, despite having similar characteristics. These results should be interpreted with caution, as the presence of confounding by indication and residual confounding in this analysis underscores the need for randomized clinical trials in this population.
Reference Key
openalex_W7220657720 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Carmine Valenza, Yue Zheng, José Pablo Leone, Dario Trapani, Pier Paolo Maria Berton Giachetti, Guilherme Nader Marta, Laura Stewart Dominici, Sara M. Tolaney, Ann H. Partridge, Giuseppe Curigliano, Meredith M. Regan, Harold J. Burstein
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag374
URL
https://doi.org/10.1093/jnci/djag374
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.